Mehmet Mutlu Meydanli

Mehmet Mutlu Meydanli

Auto-generated profile, based on publicly available information

Mehmet Mutlu Meydanli

Department of Gynecologic Oncology, Zekai Tahir Burak Women’s Health Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2024 in International Journal of Gynecological Cancer
Verified
Journal Article
Open access
PDF file
IRIsabelle Ray-Coquard
Isabelle Ray-Coquard
PCPaolo Giovanni Casali
Paolo Giovanni Casali
SCSabrina Croce
Sabrina Croce
FFFiona M Fennessy
Fiona M Fennessy
DFDaniela Fischerova
Daniela Fischerova
MFMichael Friedlander
Michael Friedlander

1 January 2020 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
KAKoray Aslan
Koray Aslan
MMMehmet Mutlu Meydanli
Mehmet Mutlu Meydanli
MÖMurat ÖZ
Murat ÖZ
YTYusuf Aytaç Tohma
Yusuf Aytaç Tohma
AHAli Haberal
Ali Haberal
AAAli Ayhan
Ali Ayhan
The aim of this study was to determine the prognostic value of lymph node ratio (LNR) in women with 2018 International Federation of Gynecology and Obstetrics stage IIIC cervical cancer. In this retrospective dual-institutional study, a total of 185 node-positive cervical cancer patients who had undergone radical hysterectomy with systematic pelvic and para-aortic lymphadenectomy were included. All of the patients received adjuvant chemoradiation after surgery. LNR was defined as the ratio of positive lymph nodes (LNs) to the total number of LNs removed. The patients were categorized into 2 groups according to LNR; LNR <0.05 and LNR ≥0.05. The prognostic value of LNR was evaluated with univariate log-rank tests and multivariate Cox regression models. A total of 138 patients (74.6%) had stage IIIC1 disease and 47 (25.4%) patients had stage IIIC2 disease. With a median follow-up period of 45.5 months (range 3-135 months), the 5-year disease-free survival (DFS) rate was 62.5% whereas the 5-year overall survival (OS) rate was 70.4% for the entire study population. The 5-year DFS rates for LNR <0.05 and LNR ≥0.05 were 78.2%, and 48.4%, respectively (p<0.001). Additionally, the 5-year OS rates for LNR <0.05 and LNR ≥0.05 were 80.6%, and 61.2%, respectively (p=0.007). On multivariate analysis, LNR ≥0.05 was associated with a worse DFS (hazard ratio [HR]=2.12; 95% confidence interval [CI]=1.15-3.90; p=0.015) and OS (HR=1.95; 95% CI=1.01-3.77; p=0.046) in women with stage IIIC cervical cancer. LNR ≥0.05 seems to be an independent prognostic factor for decreased DFS and OS in stage IIIC cervical carcinoma.

18 May 2017 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
MSMustafa Erkan Sari
Mustafa Erkan Sari
IYİbrahim Yalcin
İbrahim Yalcin
HSHanifi Sahin
Hanifi Sahin
MMMehmet Mutlu Meydanli
Mehmet Mutlu Meydanli
TGTayfun Güngör
Tayfun Güngör

1 January 2017 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
VKVakkas Korkmaz
Vakkas Korkmaz
MMMehmet Mutlu Meydanli
Mehmet Mutlu Meydanli
IYIbrahim Yalçın
Ibrahim Yalçın
MSMustafa Erkan Sarı
Mustafa Erkan Sarı
HSHanifi Sahin
Hanifi Sahin
AAAli Ayhan
Ali Ayhan
Korkmaz V, et al. J Gynecol Oncol. 2017 Jul;28(6):e78. https://doi.org/10.3802/jgo.2017.28.e78

1 September 2019 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
AAAli Ayhan
Ali Ayhan
KAKoray Aslan
Koray Aslan
AAAYCA NAZLI AKAR
AYCA NAZLI AKAR
HAHuseyin Akilli
Huseyin Akilli
MÖMurat ÖZ
Murat ÖZ
MMMehmet Mutlu Meydanli
Mehmet Mutlu Meydanli

1 January 2020 in Journal of Gynecology Obstetrics and Human Reproduction
Verified
Journal Article
Closed access
AYAyçağ Yorgancı
Ayçağ Yorgancı
MMMehmet Mutlu Meydanlı
Mehmet Mutlu Meydanlı
NKNEZAKET KADIOĞLU
NEZAKET KADIOĞLU
STSalih Taşkın
Salih Taşkın
FKFulya Kayıkçıoğlu
Fulya Kayıkçıoğlu
AAAli Ayhan
Ali Ayhan